These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 27357178)

  • 1. Different Prognostic Implications of Residual Disease After Neoadjuvant Treatment: Impact of Ki 67 and Site of Response.
    Diaz-Botero S; Espinosa-Bravo M; Gonçalves VR; Esgueva-Colmenarejo A; Peg V; Perez J; Cortes J; Rubio IT
    Ann Surg Oncol; 2016 Nov; 23(12):3831-3837. PubMed ID: 27357178
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A prognostic model based on combining estrogen receptor expression and Ki-67 value after neoadjuvant chemotherapy predicts clinical outcome in locally advanced breast cancer: extension and analysis of a previously reported cohort of patients.
    Miglietta L; Morabito F; Provinciali N; Canobbio L; Meszaros P; Naso C; Murialdo R; Boitano M; Salvi S; Ferrarini M
    Eur J Surg Oncol; 2013 Oct; 39(10):1046-52. PubMed ID: 23890870
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pathologic complete response after neoadjuvant chemotherapy in HER2-overexpressing breast cancer according to hormonal receptor status.
    Tanioka M; Sasaki M; Shimomura A; Fujishima M; Doi M; Matsuura K; Sakuma T; Yoshimura K; Saeki T; Ohara M; Tsurutani J; Watatani M; Takano T; Kawabata H; Mukai H; Naito Y; Hirokaga K; Takao S; Minami H
    Breast; 2014 Aug; 23(4):466-72. PubMed ID: 24742606
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy.
    Tan QX; Qin QH; Yang WP; Mo QG; Wei CY
    Int J Clin Exp Pathol; 2014; 7(10):6862-70. PubMed ID: 25400769
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Prognostic Effect of Changes in Tumor Stage and Nodal Status After Neoadjuvant Chemotherapy in Each Primary Breast Cancer Subtype.
    Hayashi N; Takahashi Y; Matsuda N; Tsunoda H; Yoshida A; Suzuki K; Nakamura S; Yamauchi H
    Clin Breast Cancer; 2018 Apr; 18(2):e219-e229. PubMed ID: 29138067
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lymph Node Ratio Analysis After Neoadjuvant Chemotherapy is Prognostic in Hormone Receptor-Positive and Triple-Negative Breast Cancer.
    Tsai J; Bertoni D; Hernandez-Boussard T; Telli ML; Wapnir IL
    Ann Surg Oncol; 2016 Oct; 23(10):3310-6. PubMed ID: 27401442
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Breast cancer subtypes can be a predictor of pathologic complete response and survival in the neoadjuvant setting for T4 noninflammatory breast cancer.
    Gülben K; Berberoğlu U; Kinaş V; Başkan E
    Acta Chir Belg; 2014; 114(3):153-9. PubMed ID: 25102703
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic assessment of breast carcinoma submitted to neoadjuvant chemotherapy with pathological non-complete response.
    Resende U; Cabello C; Ramalho SOB; Zeferino LC
    BMC Cancer; 2019 Jun; 19(1):601. PubMed ID: 31208353
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-world data on breast pathologic complete response and disease-free survival after neoadjuvant chemotherapy for hormone receptor-positive, human epidermal growth factor receptor-2-negative breast cancer: a multicenter, retrospective study in China.
    Guan D; Jie Q; Wu Y; Xu Y; Hong W; Meng X
    World J Surg Oncol; 2022 Sep; 20(1):326. PubMed ID: 36175898
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Change in Biomarker Profile After Neoadjuvant Chemotherapy is Prognostic and Common Among Patients with HER2+ Breast Cancer.
    Tchou J; Gottipati S; Goldbach M; Baxter M; Venters S; Balassanian R; Vohra P; Gonzalves D; Ahmad Z; Nayak A; Boughey JC; Mukhtar RA; Chen YY
    Ann Surg Oncol; 2024 Nov; 31(12):8093-8101. PubMed ID: 39117925
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High expression of post-treatment Ki-67 status is a risk factor for locoregional recurrence following breast-conserving surgery after neoadjuvant chemotherapy.
    Yamazaki N; Wada N; Yamauchi C; Yoneyama K
    Eur J Surg Oncol; 2015 May; 41(5):617-24. PubMed ID: 25771264
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Different prognostic significance of Ki-67 change between pre- and post-neoadjuvant chemotherapy in various subtypes of breast cancer.
    Matsubara N; Mukai H; Fujii S; Wada N
    Breast Cancer Res Treat; 2013 Jan; 137(1):203-12. PubMed ID: 23184081
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Response of Triple Negative Breast Cancer to Neoadjuvant Chemotherapy: Correlation between Ki-67 Expression and Pathological Response.
    Elnemr GM; El-Rashidy AH; Osman AH; Issa LF; Abbas OA; Al-Zahrani AS; El-Seman SM; Mohammed AA; Hassan AA
    Asian Pac J Cancer Prev; 2016; 17(2):807-13. PubMed ID: 26925684
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of Elective Nodal Irradiation in Patients With ypN0 After Neoadjuvant Chemotherapy Followed by Breast-Conserving Surgery (KROG 16-16).
    Cho WK; Park W; Choi DH; Kim YB; Kim JH; Kim SS; Kim K; Kim JH; Ahn SJ; Lee SY; Lee J; Kim SW; Kwon J; Ahn KJ
    Clin Breast Cancer; 2019 Feb; 19(1):78-86. PubMed ID: 30241965
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical significance of Ki-67 in neoadjuvant chemotherapy for primary breast cancer as a predictor for chemosensitivity and for prognosis.
    Nishimura R; Osako T; Okumura Y; Hayashi M; Arima N
    Breast Cancer; 2010 Oct; 17(4):269-75. PubMed ID: 19730975
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Beyond Axillary Lymph Node Metastasis, BMI and Menopausal Status Are Prognostic Determinants for Triple-Negative Breast Cancer Treated by Neoadjuvant Chemotherapy.
    Bonsang-Kitzis H; Chaltier L; Belin L; Savignoni A; Rouzier R; Sablin MP; Lerebours F; Bidard FC; Cottu P; Sastre-Garau X; Laé M; Pierga JY; Reyal F
    PLoS One; 2015; 10(12):e0144359. PubMed ID: 26684197
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How Often Is Treatment Effect Identified in Axillary Nodes with a Pathologic Complete Response After Neoadjuvant Chemotherapy?
    Barrio AV; Mamtani A; Edelweiss M; Eaton A; Stempel M; Murray MP; Morrow M
    Ann Surg Oncol; 2016 Oct; 23(11):3475-3480. PubMed ID: 27469123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Effect of Molecular Subtype and Residual Disease on Locoregional Recurrence in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy and Postmastectomy Radiation.
    Yang TJ; Morrow M; Modi S; Zhang Z; Krause K; Siu C; McCormick B; Powell SN; Ho AY
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3(Suppl 3):S495-501. PubMed ID: 26130454
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High Ki67 predicts unfavourable outcomes in early breast cancer patients with a clinically clear axilla who do not receive axillary dissection or axillary radiotherapy.
    Zurrida S; Bagnardi V; Curigliano G; Mastropasqua MG; Orecchia R; Disalvatore D; Greco M; Cataliotti L; D'Aiuto G; Talakhadze N; Goldhirsch A; Viale G
    Eur J Cancer; 2013 Oct; 49(15):3083-92. PubMed ID: 23777741
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HER2-positive is an independent indicator for predicting pathological complete response to neoadjuvant therapy and Ki67-changed after neoadjuvant chemotherapy predicts favorable prognosis in Chinese women with locally advanced breast cancer.
    Fang Y; Zhang Q; Wu Y; Wu J
    Medicine (Baltimore); 2024 Feb; 103(6):e37170. PubMed ID: 38335419
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.